Skip to main content
SpringerLink
Log in

Prostata

  • Chapter
Männersprechstunde

  • 66 Accesses

Zusammenfassung

Die benigne Prostatahyperplasie — obgleich eigentlich eine histologische Diagnose — hat lange Zeit als Überbegriff für die klinische Definition einer vergrößerten Prostata mit assoziierten Miktionsbeschwerden gedient. Nach den aktuellen Leitlinien der Deutschen Urologen sollte für das bisher mit „Benigne Prostatahyperplasie (BPH)“ bezeichnete Krankheitsbild fortan die Bezeichnung „Benignes Prostata-Syndrom (BPS)“ Verwendung finden, um damit einen neuen Überbegriff für die pathophysiologisch sehr variable Relation zwischen Miktionssymptomatik (lower urinary tract Symptoms, LUTS), Prostatavergrößerung (benign prostatic enlargement, BPE) und Obstruktion (bladder outlet obstruction, BOO, bzw. benign prostatic obstruction, BPO) zu etablieren (Leitlinien 2003a). Die alte Bezeichnung „BPH“ sollte — wie im TNM-System — als „pBPH“ (p für pathologisch-histologisch) gekennzeichnet und ausschließlich in diesem Kontext verwendet werden. Differenzialdiagnostisch sind nicht durch eine BPH bedingte Miktionssymptome auszuschließen. Letztlich muss die Diagnostik klären, in welchem Verhältnis Miktionssymptome (LUTS), eine Obstruktion des Blasenauslasses (BOO) infolge einer benignen Prostataobstruktion (BPO) und die Vergrößerung der Prostata (BPE) per se stehen (Leitlinien 2003a).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anderson B, Roehrborn CG, Schalken JA, Emberton M (2001) The progression of benign prostatic hyperplasia: examining the evidence and determing the risk. Eur Uro 139: 390–399

    Google Scholar 

  • Arrighi HM, Metter EJ, Guess HA, Fozzard JL (1991) Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 38 (Suppl): 4–8

    PubMed  CAS  Google Scholar 

  • Bautista OM, Kusek JW, Nyberg LM et al. (2003) Study design of the medical therapy of prostatic symptoms (MTOPS) trial. Control Clin Trials 24: 224–243

    PubMed  Google Scholar 

  • Berges RR, Pientka L (1999) Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 36 (Suppl3): 21–27

    PubMed  Google Scholar 

  • Berges RR, Pientka L, Hofner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Uro I 39:682–687

    CAS  Google Scholar 

  • Delakas D, Lianos E, Karyotis I, Cranidis A (2001) Finasteride: a longterm follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol lnt 67: 69–72

    CAS  Google Scholar 

  • Dreikorn K, Berges R, Pientka L, Jonas U (2002) Phytotherapie bei BPH. Urologe A 41: 447–451

    PubMed  CAS  Google Scholar 

  • Edwards JE, Moore RA (2002) Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomized trials. BMC Urology 2: 14

    PubMed  Google Scholar 

  • Fornara P, Semjonow A (2002) PSA: Der Weg zum Befund. Zuckschwerdt, Munchen, pp 1–15

    Google Scholar 

  • Gaynor ME (2003) Isoflavones and the prevention and treatment of prostate disease. Cleveland Clinic J Med 70: 203–216

    Google Scholar 

  • Gerber G (2002) Phytotherapy for benign prostatic hyperplasia. Current Urol Rep 3: 285–291

    Google Scholar 

  • Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM (1999) Association of health-related quality of life and benign prostatic enlargement. Eur Uro 135: 277–284

    Google Scholar 

  • Gonzalez CM, McVary KT (2003) The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 4: 276–281

    PubMed  Google Scholar 

  • Jacobsen SJ, Girman CJ, Guess HA et al. (1993) Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993 42: 663–671

    CAS  Google Scholar 

  • Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM (1999) Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162: 1301–1306

    PubMed  CAS  Google Scholar 

  • Jacobsen SJ, Girman CJ, Lieber MM (2001) Natural history of benign prostatic hyperplasia. Urology 58 (Suppl 1): 5–16

    PubMed  CAS  Google Scholar 

  • Klein EA (2003) Supplements and the prostate: Widespread use, little evidence. Cleveland Clinic J Med 70: 169–176

    Google Scholar 

  • Larsen TR (2003) Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology 61: 692–698

    Google Scholar 

  • Leitlinien (2003a): Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe 42: 584–590

    Google Scholar 

  • Leitlinien (2003b): Leitlinien der Deutschen Urologen zur Therapie des benignen Prostatasyndroms (BPS). http://www.uniduesseldorf. de/AWMF/ll/index.html

    Google Scholar 

  • Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB (2001) Riskfactors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54: 935–944

    PubMed  CAS  Google Scholar 

  • Prezioso D, Catuogno C, Galassi P, D’Andrea G, Castello G, Pirritano D (2001) Life-style in patients with LUTS suggestive of BPH. Eur Urol 40 (Suppl 1): 9–12

    PubMed  Google Scholar 

  • Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM (1999) Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161: 1174–1179

    PubMed  CAS  Google Scholar 

  • Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM (1997) Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 157: 1711–1717

    PubMed  CAS  Google Scholar 

  • Roehrborn CG (2002) Are all alpha-blockers created equal? An update. Urology 59 (Suppl 2A): 3–6

    PubMed  Google Scholar 

  • Roehrborn CG, Bruskewitz R, Nickel GC et al. (2000) Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. Eur Urol 37: 528–536

    PubMed  CAS  Google Scholar 

  • Roehrborn CG, Malice M, Cook TJ, Girman CJ (2001) Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58: 210–216

    PubMed  CAS  Google Scholar 

  • Roehrborn CG, Boyle P, Nickel JE, Hoefner K, Andriole G; ARIA3001, ARIA3002 and ARIA3003 Study Investigators (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60: 434–441

    PubMed  Google Scholar 

  • Sakeland J, Sakeland A (2003) Naturheilverfahren in der Urologie. Springer, Berlin Heidelberg New York Tokio, pp 103–127

    Google Scholar 

  • Wessells H, Roy J, Bannow J et al. (2003) Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 61: 579–584

    PubMed  Google Scholar 

  • Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW, Carter HB (2002) Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 167: 2484–2487

    PubMed  Google Scholar 

  • Adolfsson J (1995) Radical prostatectomy, radiotherapy or deferred treatment for localized prostate Cancer? Cancer Surv 23:141–148

    PubMed  CAS  Google Scholar 

  • Arzneimittelkommission (2000): Arzneimittelkommission der deutschen Ärtzeschaft. Hinweise zur sicheren Verordnung von Sildenafil (Viagra). Dtsch Ärztebl 97: A199

    Google Scholar 

  • Bales GT, Chodak GW (1996) A controlled trial of bicalutamide versus castration in patients with advanced prostate Cancer. Urology 41:38–43

    Google Scholar 

  • Benson M, Whang I, Pantuck A et al. (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate Cancer. J Urol 147:815–821

    PubMed  CAS  Google Scholar 

  • Blute ML, Zincke H, Farrow GM (1986) Long-term followup of young patients with stage A adenocarcinoma of the prostate. J Urol 136: 840–843

    PubMed  CAS  Google Scholar 

  • Brawer M, Chetner M (1997) Ultrasonography of the prostate and biopsy. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2506–2518

    Google Scholar 

  • Brawer MK, Cheli CD, Neaman IE et al. (2000) Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate Cancer. J Urol 163:1476–1480

    PubMed  CAS  Google Scholar 

  • Carter H, Pearson J (1993): PSA velocity for the diagnosis of early prostate Cancer. Urol Clin North Am 20:665–670

    PubMed  CAS  Google Scholar 

  • Carter H, Partin A (1997) Diagnosis and Staging of prostate Cancer. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2519–2537

    Google Scholar 

  • Catalona WJ, Smith DS (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate Cancer. JUrol 152:1837–1842

    CAS  Google Scholar 

  • Catalona WJ, Partin AW, Slawin KM et al. (1998) Use the percentage of free prostate-specific antigen to enhance differentiation of prostate Cancer from benign prostatic disease. JAMA 279:1542–1547

    PubMed  CAS  Google Scholar 

  • Collins GN, Lloyd SN, Hekir M, McKelvie GB (1993) Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity ans acceptance. Br JUrol 71:460–463

    CAS  Google Scholar 

  • Davidson PJ, Hop W, Kurth KH et al. (1995) Progression in untreated Carcinoma of the prostate metastatic to regional lymph nodes (stage tO to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 154: 2118–2122

    PubMed  CAS  Google Scholar 

  • De Koning HJ, Liem MK, Baan CA et al. (2002) Prostate Cancer mortality reduction by Screening: Power and time frame with complete enrollment in the european randomised Screening for prostate Cancer (ERSPC) trial. Int J Cancer 98:268–273

    PubMed  Google Scholar 

  • Eichholzer M, Stahelin HB, Ludin E, Bernasconi F (1999) Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate Cancer: seventeen-year follow-up of the prospective basel study. Prostate 38:189–198

    PubMed  CAS  Google Scholar 

  • Epstein JI, Oesterling JE, Walsh PC (1988) The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate Cancer. J Urol 139:975–9

    PubMed  CAS  Google Scholar 

  • Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathological and clinical findings to predict tumor extent of non-palpable (stage T1 c) prostate Cancer. JAMA 271:368–374

    PubMed  CAS  Google Scholar 

  • Fachgesellschaften (2002): Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften. S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms), www.awmf-online.de <reference>(1993) Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 149: 516–518

    Google Scholar 

  • Geary ES, Dendinger TE, Freiha FS, Stamey TA (1995) Nerve sparing radical prostatectomy: a different view. J Urol 154:145–149

    PubMed  CAS  Google Scholar 

  • Gronberg H, Isaacs SD, Smith JR et al. (1997) Characteristics of prostate Cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. Jama 278:1251–1255

    PubMed  CAS  Google Scholar 

  • Gronberg H, Wiklund F, Damber JE (1999) Age specific risks offamilial prostate Carcinoma: a basis for Screening recommendations in high risk populations. Cancer 86:477–483

    PubMed  CAS  Google Scholar 

  • Hampson SJ, Davies JH, Charig CR, Shearer RJ (1993) LHRH analogues as primary treatment for urinary retention in patients with prostatic Carcinoma. Br J Urol 71:583–586

    PubMed  CAS  Google Scholar 

  • Hebert JR, Hurley TG, Olendzki BC et al. (1998) Nutritional and socioeconomic factors in relation to prostate cancer mortality: a crossnational study. J Natl Cancer Inst 90:1637–1647

    PubMed  CAS  Google Scholar 

  • Hoedemaeker RF, Rietbergen JB, Kranse R et al. (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based Screening. J Urol 164:411–415

    PubMed  CAS  Google Scholar 

  • Krebsregister (2002): Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland, 3. Aufl. Saarbrücken, www.rki.de

    Google Scholar 

  • Lilja H (2001) Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 39 (Suppl 4): 47–48

    PubMed  Google Scholar 

  • Luboldt HJ, Rübben H (2000) PSA-Früherkennung des Prostatakarzinoms. Urologe A 39:22–26

    PubMed  CAS  Google Scholar 

  • Luboldt HJ, Altwein JE, Bichler KH et al. (1999) Früherkennung des Prostatakarzinoms. Erste Ergebnisse einer prospektiven multizentrischen Studie in Deutschland. Urol A 38:114–123

    CAS  Google Scholar 

  • Murphy GP, Mettlin C, Menck H et al. (1994) National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 152:1817–1819

    PubMed  CAS  Google Scholar 

  • Neri R, Kassem M (1984) Biological and clinical properties of antiandrogens. Prog Cancer Res Ther 31:507–518

    CAS  Google Scholar 

  • Oesterling J, Jacobsen S, Chute C et al. (1993) Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864

    PubMed  CAS  Google Scholar 

  • Ohori M, Goad JR, Wheeler TM et al. (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843–1849

    PubMed  CAS  Google Scholar 

  • Partin AW, Yoo J, Carter HB et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150,110–114

    PubMed  CAS  Google Scholar 

  • Partin AW, Mangold LA, Lamm DM et al. (2001) Contemporary update of prostate cancer Staging nomograms (Partin Tables) for the new millennium. Urology 58:843–848

    PubMed  CAS  Google Scholar 

  • Pienta K ( 1997) Etiology, epidemiology and prevention of Carcinoma of the prostate. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2489–2496

    Google Scholar 

  • Pilepich MV, Caplan R, Byhardt RW et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis Carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 15:1013–1021

    PubMed  CAS  Google Scholar 

  • Price CP, Allard J, Davies G et al. (2001) Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a Screening Programme for prostate cancer. Ann Clin Biochem 38:188–216

    PubMed  CAS  Google Scholar 

  • Scher HI, Kelly WK (1993) Flutamide withdrawal Syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572

    PubMed  CAS  Google Scholar 

  • Schröder F (1997) Endocrine treatment of prostate cancer. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2627–2644

    Google Scholar 

  • Semjonow A, Zechel C, Brandt B et al. (1995) Teststreifenuntersuchungen. Prostataspezifisches Antigen (PSA). Urol A 34 (Suppl 1): 91

    Google Scholar 

  • Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A (1995) Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154:424–428

    PubMed  CAS  Google Scholar 

  • Stenman U, Leinonen J, Alfthan H et al. (1991) A complex between prostate-specific antigen an alphal-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222–226

    PubMed  CAS  Google Scholar 

  • Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus Prednisone or Prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    PubMed  CAS  Google Scholar 

  • Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152:1831–1836

    PubMed  CAS  Google Scholar 

  • Adlercreutz H, Mazur W (1997) Phyto-oestrogens and Western diseases. Ann Mediane 29:95–120

    CAS  Google Scholar 

  • Bratt O (2002) Hereditary prostate cancer: clinical aspects. J Urol 168: 906–913

    PubMed  Google Scholar 

  • Clark LC, Combs Jr GF, Turnbull BW et al. For the Nutritional Prevention of Cancer Study Group (1996) Effects of Selenium supplementation for cancer prevention in patients with Carcinoma of the skin: a randomized controlled clinical trial. JAMA 276:1957–1963

    Google Scholar 

  • Corder EH, Guess HA, Hulka BS et al. (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467–472

    PubMed  CAS  Google Scholar 

  • Eichholzer, Stahelin HB, Gey KF, Ludin E, Bernasconi F (1996) Prediction of male cancer mortality by plasma levels of interacting Vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66:145–150

    PubMed  CAS  Google Scholar 

  • Giovannucci E, Rimm EB, Colditz GA et al. (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85: 1571–1579

    PubMed  CAS  Google Scholar 

  • Hammerer P, Graefen M, Steuber T, Huland H (2000) Chemoprävention des Prostatakarzinoms. Urologe A 39:304–308

    PubMed  CAS  Google Scholar 

  • Hanchette CL, Schwartz GG (1992) Geographie patters of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861–2869

    PubMed  CAS  Google Scholar 

  • Hartman TJ, Albanes D, Pietinen P et al. (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7:335–340

    PubMed  CAS  Google Scholar 

  • Heinonen OP, Albanes D, Virtamo J et al. (1998) Prostate cancer and supplementation with a-tocopherol and ß-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446

    PubMed  CAS  Google Scholar 

  • Helzlsouer KJ, Huang HY, Alberg AJ et al. (2000) Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl cancer Inst 92:2018–2023

    PubMed  CAS  Google Scholar 

  • Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23:3–13

    PubMed  CAS  Google Scholar 

  • Jankevicius F, Miller SM, Ackermann R (2002) Nutrition and risk of prostate cancer. Urol Int 68:69–80

    PubMed  CAS  Google Scholar 

  • Klein EC, Thompson IM, Lippman SM et al. (2001) SELECT: the next prostate cancer prevention trial. J Urol 166:1311–1315

    PubMed  CAS  Google Scholar 

  • Madersbacher S, Haidinger G, Temml C, Schmidbauer CP for the Prostate Study Group of the Austrian Society of Urology (1998) The prevalence of lower urinary tract Symptoms in Austria as assessed by an open survey of 2096 men. Eur Urol 34:136–141

    PubMed  CAS  Google Scholar 

  • Madersbacher S, Schatzl G, Gsur A et al. (2002) Spielen Phytoöstrogene eine Rolle in der Pathogenese des Prostatakarzinoms in westlichen Industrieländern. Urologe A (Suppl 1): S 5

    Google Scholar 

  • McConnell JD, Bruskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338:557–563

    PubMed  CAS  Google Scholar 

  • Moyad MA (2002) Selenium and vitamin E Supplements for prostate cancer: evidence or embellishment. Urology 59 (Suppl 4A): 9–19

    PubMed  Google Scholar 

  • Nomura AM (2001) Body size and prostate cancer. Epidem Reviews 23:126–131

    CAS  Google Scholar 

  • Oishi K, Okada K, Yoshida O et al. (1988) A case-control study of prostatic cancer with reference to dietary habits. Prostate 12: 179–190

    PubMed  CAS  Google Scholar 

  • Roehrborn CG, Boyle P, Nickel JC et al. for ARIA3001, ARIA3002 and ARIA3003 Study Investigators (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441

    PubMed  Google Scholar 

  • Schmitz-Dräger BJ, Savov O, Fischer C, Ebert T, Altwein J (2002) Ernährung und Prostatakrebs. Urologe B 42:28–292

    Google Scholar 

  • Schulman CC, Anderson B, Bangma CH, Marberger MJ (2002) Prevention and Screening. Eur Urol (Suppl 1): 3–9

    Google Scholar 

  • Vutuc C, Waldhoer T, Madersbacher S, Micksche M, Haidinger G (2001) Prostate cancer in Austria: impact of prostate-specific antigen teston incidence and mortality. Eur J Cancer Prev 10:425–428

    PubMed  CAS  Google Scholar 

  • Wang Y, Corr JG, Thaler HT et al. (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87:1456–1462

    PubMed  CAS  Google Scholar 

  • Woolf CM (1960) An investigation of familial aspects of Carcinoma of the prostate. Cancer 13: 739–744

    PubMed  CAS  Google Scholar 

  • Altwein J (1998) Diagnostik, Klinik und Therapie. In: Helpap B, Rübben H (Hrsg) Das Prostatakarzinom. Pathologie, Praxis und Klinik. Springer, Berlin Heidelberg New York Tokio

    Google Scholar 

  • Bairati I, Meyer F, Fradet Y, Moore L (1998) Dietary fat and advanced prostate cancer. J Urol 159:1271–1275

    PubMed  CAS  Google Scholar 

  • Behre HM (1994) Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 40: 341–349

    CAS  Google Scholar 

  • Carson C, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 (Suppl 1):2–7

    PubMed  Google Scholar 

  • Curran MJ, Bihrle W (1999) Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53:423–424

    PubMed  CAS  Google Scholar 

  • Davies P, Eaton CL (1991) Regulation of prostate growth. J Endocrinol 131:5–9

    PubMed  CAS  Google Scholar 

  • Diemer T, Desjardins C (1999) Developmental and genetic disorders in spermatogenesis. Hum Reprod Update 5:120–140

    PubMed  CAS  Google Scholar 

  • Diemer T, Haies DB, Weidner W (2003) Immune-endocrine interactions and Leydig cell function: the role of cytokines. Andrologia 35:55–63

    PubMed  CAS  Google Scholar 

  • Feldman HA, Longcope C, Derby CA et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589–598

    PubMed  CAS  Google Scholar 

  • Ferri M, Norman RW (2000) Prostate cancer in a hypogonadal male receiving androgen supplementation. Can J Urol 7:1055–1056

    PubMed  CAS  Google Scholar 

  • Fowler JE Jr, Whitmore WF Jr (1981) The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126:372–375

    PubMed  Google Scholar 

  • Frick J, Jungwirth A, Rovan E (1998) Androgens and the prostate. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, Substitution. Springer, Berlin Heidelberg New York Tokio

    Google Scholar 

  • Gann PH, Hennekens CH, Sacks FM et al. (1994) Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86:281–286

    PubMed  CAS  Google Scholar 

  • Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD (2002) Prostatespecific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 23:922–926

    PubMed  Google Scholar 

  • Gruenewald DA, Matsumoto AM (2003) Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 51:101–115

    PubMed  Google Scholar 

  • Heikkila R, Aho K, Heliovaara M et al.(1999) Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate Carcinoma: a longitudinal study. Cancer 86:312–315

    PubMed  CAS  Google Scholar 

  • Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57: 216–218

    PubMed  CAS  Google Scholar 

  • Hoffman MA, De Wolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163:824–827

    PubMed  CAS  Google Scholar 

  • Jin B, Conway AJ, Handelsmann DJ (20001) Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol 54:437–445

    Google Scholar 

  • Krebsregister (1999): Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland: Häufigkeiten und Trends, 2. Aufl.

    Google Scholar 

  • Moradi T, Delfino RJ, Bergstrom SR, Yu ES, Adami HO, Yuen J (1998) Cancer risk among Scandinavian immigrants in the US and Scandinavian residents compared with US whites, 1973–89. Eur J Cancer Prev 7:117–125

    PubMed  CAS  Google Scholar 

  • Morgentaler A, Brüning B, De Wolf WC (1996) Occult prostate cancer in men with low serum testosterone levels. JAMA 276:1904–1906

    PubMed  CAS  Google Scholar 

  • Oishi K, Yoshida O, Schroeder FH (1995) The geography of prostate cancer and its treatment in Japan. Cancer Surv 23:267–280

    PubMed  CAS  Google Scholar 

  • Oliver RT, Williams G, Paris AM, Blandy JP (1997) Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49:79–82

    PubMed  CAS  Google Scholar 

  • Paiss G, Gschwend JE, Maier C, Eisele M, Vogel W, Nautmann RE, Nerkammer K (2002) Preventing prostata Carcinoma in men with familial disposition. Urologe A 41 (6): 596–601

    PubMed  CAS  Google Scholar 

  • Partin AW, Coffey DS (1998) The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC et al. (eds) Campbell’s Urology, 7th edn. Saunders, Philadelphia

    Google Scholar 

  • Pollard M, Lückert PH (1986) Promotional effects of testosterone and high fat diet on the development of autochthonous prostate Cancer in rats. Cancer Lett 32:223–227

    PubMed  CAS  Google Scholar 

  • Prins GS, Birch L (1995) The developmental pattern of androgen receptor regulation in the rat prostate lobes is altered following neonatal exposure to estrogen. Endocrinology 136:1303–1314

    PubMed  CAS  Google Scholar 

  • Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20:605–608

    PubMed  CAS  Google Scholar 

  • Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887–889

    PubMed  CAS  Google Scholar 

  • Ross RK, Pike MC, Coetzee GA et al. (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497–4504

    PubMed  CAS  Google Scholar 

  • Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA (1994) Association of energy and fat intake with prostate Carcinoma risk: results from The Netherlands Cohort Study. Cancer 86:1019–1027

    Google Scholar 

  • Shaneyfelt T, Nascin R, Bubley G, Mantzoros CS (2000) Normonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18 (4): 847–853

    PubMed  CAS  Google Scholar 

  • Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr (1997) The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 158:1775–1777

    PubMed  CAS  Google Scholar 

  • Tenover JL (1997) Androgen administration to aging men. Endocrinol Metab Clin North Am 23:877–886

    Google Scholar 

  • Tenover JL (1998) Androgen deficiency in aging men. Aging Male 1 (Suppl 1): 16–21

    Google Scholar 

  • Thomas JA, Keenan EJ (1994) Effects of estrogens on the prostate. J Androl 15:571–575

    Google Scholar 

  • Wilson DW, Harper ME, Jensen HM et al. (1985) Prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation. Prostate 7:131–141

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. Jocham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Doehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Börgermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Swoboda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Lümmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Madersbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Ponholzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. Diemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Jocham, D. et al. (2004). Prostata. In: Männersprechstunde. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18705-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18705-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00915-3

  • Online ISBN: 978-3-642-18705-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation